Company profile

Aromics

DrugScreening

Molecular BiologyPharmacology

In vivostudies

Proteomics

Biochemistry

Genomics

Pharmacogenetics Cellbiology

Engineering

AROMICS is a development stage biotechnology company founded in 2005, currently located at the Scientific Park of Barcelona (PCB).

new specific targeted compound with higher efficacy & safety

A diagnostic method to monitor the disease & patient response

Product Pipeline

AROMICS is actively involved in internal & collaborative projects with pharmaceutical and biotech companies for developing new effective and safer drugs.

* Our development are partially financed through European Union, National, Regional and Private funding

AROMICS partners relevant scientific, technological and industrial actors for its developments in the diagnostic field, focusing on health (human & animal), agro-food and environment sectors.

Active development License and co-development opportunities

Recognition material

Electrical signal

Principle : A biosensor is an analytical device capable of providing selective quantitative or semi-quantitative analytical information due to the specific biological recognition among the element/analyte of interest and the recognising element.

Aromics: Projecte Mercurius

Nucleic AcidAntibodyEnzyme

RecceptorCell-organelle

Whole cellTissue

Signal Transducers

Electroactive substanceLight

Mass change

HeatpH

Electrode

PMT, CCD

PiezoelectricSPR

Temperature sensorpH electrode

POC testing: Analytical tools for the in-situ detection of pathogens by a rapid and low cost assay.

In-situ detection of legionella by a rapid and low cost assay in water samples.

Magnetic bead-based biosensor: Immunolegio®

•Magnetic nanoparticles (100-300 nm) functionalized with specific Antibodies for the pathogen of interest

Operational procedure

•Legionella pneumonia is found in aquatic habitats(potable water systems, cooling towers, heat exchanger systems). •Important pathogen: Causes pneumonia. •Rates of mortality: 12% in Europe. Sanitary cost in Spain: 12M€•Conventional techniques have not prevention utility•Classical immunological assays take 12 to 15 days to get a result

WaterAutomatic sample prep

Immunoassay trends: biomarkers are increasingly being measured at the sites of patient care, including the doctor’s office and emergency room, allowing for rapid estimates of the state or progress of an illness, and even at home, for the purposes of self-diagnosis.

With respect infectious diseases, there are two important goals: prevention and focus control & propagation. The ideal immuno-analytical system does not require a complex sample procedure, is easy to operate, fast, allowing to take rapid decissions in-field and has a low cots.

The system is intended to be used for surveillance purposes and to complement conventional methods.

Economic impact:•Growing market: at 11% a year. •POC testing accounts for 35-40% of the global in-vitro diagnostic (IVD) testing market. (US$30 billion).•Diagnostic testing represents between 1-2% of government healthcare expenditures worldwide and influences between 60-70% of healthcare decisions

What the market requires?

Nombre de la compañía Applied Research using Omic Sciences S.L.

Nombre del Producto / servicio:

Dispositivo point-of-care para detección de patógenos

Cliente / s objetivos /s: Empresas del sector agroalimentario y medioambiental

Breve descripción técnica:Test de diagnóstico molecular basado en tecnología biosensora para la detección de patógenos en muestras complejas

Características diferenciales respecto de la competencia:

Reducción del tiempo de respuesta del resultado en 30 min y del coste de análisis, dispositivo de campo, manipulado por cualquier tipo de usuarios y con un elevado grado de especificidad y sensibilidad.

Beneficio que aporta en el cliente (impacto económico y social):

Mejora en el diagnósticoAplicación en trazabilidad alimentariaAplicación de normativas y legislación en agroalimentación y medioambiente

Beneficios que aporta a la empresa (cualitativo y cuantitativo):

Disminución del coste de análisis con respecto a la normativa actualRealización de un mayor número de pruebas en el momento que la empresa considere oportuno.Acceso a mercados internacionalesPortabilidad y fácil de usar (no necesidad de tener personal especializado)

Estado de desarrollo: Prototipo Time to market:De 1 a 2 años, dependiendo de obtención de marca CE y validación

Mercado objetivo estimado: 5.000.000 €Otra información de interés:

Contacto: Applied Research using Omic Sciences S.L.

Aromics: projecte Mercurius

Quantitative measurementsRapid and reliable information Selective and sensitiveLow limit of detectionPortable instrumentUser-friendly platform – fast and easyRecordable, printable and diverse data system compatible readout Easily configured for different analytes On-line applications

Thank you

www.aromics.esinfo@aromics.es

carme.plasencia@aromics.es